摘要
目的观察Bevacizumab联合曲安奈德(TA)玻璃体腔注射治疗脉络膜新生血管(CNV)的近期疗效和安全性。方法收集2008年4月至2010年1月在我院确诊有CNV的21例(42眼),右眼(21眼)定为对照组,行Bevacizumab玻璃体腔注射(0.1ml),左眼(21眼)定位观察组,行Bevacizumab联合曲安奈德玻璃体腔注射(Bevacizumab和TA各0.05ml)。同一患者的左右眼同一时间进行治疗,每4周进行一次重复治疗,共4次;在第12周时,对比观察治疗前后两组最佳矫正视力变化的差异、CNV病灶渗漏情况以及黄斑区视网膜厚度变化的差异。结果两组治疗前后最佳矫正视力变化的差异无统计学意义(P>0.05)。两组治疗前后CNV病灶渗漏情况的差异无统计学意义(P>0.05)。对照组中,OCT显示黄斑区视网膜水肿在治疗后有14眼完全消退,5眼明显轻,2眼无明显变化。观察组中,20眼水肿完全消退,1眼明显减轻。两组治疗前后黄斑视网膜水肿的差异具有统计学意义(P<0.05)。结论 Bevacizumab联合曲安奈德(TA)玻璃体腔注射可以安全有效地治疗CNV,减轻黄斑视网膜水肿,延缓视力下降。
Objective To observe the efficacy and safety of intravitreal injection of Bevacizumab combined with triamcinolone acetonide（TA） for choroidal neovascularization（CNV）.Methods 21 patients diagnosed with CNV（42 eyes） from April 2008 to January 2010 in our hospital were enrolled in the experiment,its right eyes（21 eyes） were used as control group and treated with intravitreal Bevacizumab injection（0.1ml）;the left eyse（21 eyes） were used as observation group and treated with intravitreal injection of Bevacizumab in combination with triamcinolone acetonide（0.05ml）,once every 4 weeks,a total of 4 times.The best corrected visual acuity,CNV lesion leakage and macular retinal thickness in the two groups before and 12 weeks after treatment were observed and compared.Results The differences of best corrected visual acuity and leakage in CNV lesions before and after treatment between the two groups showed no statistical significance（P〈0.05）.Optic coherence tomography showed macular edema in 14 eyes was disappeared,5 eyes reduced and 2 eyes had no change after treatment in control group,however,edema was completely subsided in 20 eyes of observation group.Macular edema before and after treatment in both groups was statistically significant difference（P〈0.05）.Conclusion Intravitreal injection of Bevacizumab combined with triamcinolone acetonide is safe and effective for CNV,which can reduce macular edema,delay visual loss.
出处
《咸宁学院学报（医学版）》
2011年第3期203-205,共3页
Journal of Xianning Univarsity(medical Sciences)
